Market Overview

The Global Pharmacovigilance and Drug Safety Software Market reached US$ 1.2 billion in 2023 and is expected to reach US$ 2.5 billion by 2031, growing with a CAGR of 9.5% during the forecast period 2024-2031. Pharmacovigilance and drug safety software are essential for managing global drug safety data, focusing on identifying, reporting, and handling adverse drug reactions. This software supports effective drug regulation, clinical practices, and public health programs. Rising adoption in outsourcing firms ensures safe manufacturing processes worldwide.

Get a Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.datamintelligence.com/download-sample/pharmacovigilance-and-drug-safety-software-market

Market Dynamics: Drivers & Restraints

Increasing developments in pharmacovigilance and drug safety software drive market growth by upgrading existing tools for better safety issue detection and reporting. Enhanced algorithms improve adverse reaction monitoring and data management efficiency. For example, Merck KGaA adopted ArisGlobal's upgraded suite for better compliance and productivity. Government emphasis on adverse event monitoring further boosts demand.

Growing concerns over adverse drug reactions propel the pharmacovigilance and drug safety software market, as side effects rise due to quality issues and illegal chemicals. This leads to more secondary hospital visits and complications. According to the CDC, 1.3 million emergency visits occur annually from such events. Pressure from agencies for safe drugs accelerates software adoption.

Lack of awareness among healthcare professionals hampers pharmacovigilance and drug safety software market growth, with underreporting of reactions due to insufficient training. In India, 68% of doctors and 80% of nurses lack knowledge of national systems. This hinders program implementation and patient safety efforts. Cultural barriers exacerbate the issue in many regions.

Regional Insights

North America holds 41.3% market share due to robust IT sectors and awareness programs. Key players like ArisGlobal and IQVIA drive growth through R&D. Conferences expand knowledge on drug safety management. Europe benefits from initiatives like the EU2P project, now including North America for global risk understanding.

Asia-Pacific emerges as the fastest-growing region with rising outsourcing and regulatory pressures. Incidences of adverse effects increase demand for advanced software. Government agencies push for reliable drugs, boosting interconnected services. Middle East and Africa show potential with improving healthcare infrastructure.

Market Segmentation Analysis

By mode of delivery, cloud-based segments lead with 43.2% share, offering access to small organizations for reliable surveillance. United BioSource migrated to Oracle Argus Cloud for agile management. On-premise options persist for data control needs. Others include hybrid models.

By functionality, adverse event reporting software dominates due to regulatory needs. Issue tracking and audit tools support compliance. Drug safety audit software aids in efficient analysis. Integration of AI enhances signal detection across segments.

By end-user, contract research organizations lead with outsourcing trends. Biotechnological firms and healthcare providers follow for streamlined operations. Others include pharma companies focusing on post-market surveillance.

Recent Developments

In 2022, ArisGlobal expanded Lifesphere safety adoption with Pegbio Co., Ltd for in-house operations and cloud services. Clinigen acquired Drug Safety Navigator Inc. to enhance pharmacovigilance offerings. Stanley Capital Partners acquired MyMeds&Me to boost technology platforms. These moves strengthen global capabilities.

Key Players

Major players include Ennov Solutions Inc., Oracle Corporation, ArisGlobal LLC, EXTEDO, Clinevo Technologies, IQVIA, AB Cube, ICON Plc, Parexel International Corporation, and Accenture. These firms innovate in AI integration and compliance tools.

Key Highlights of Report

Market Growth: The pharmacovigilance and drug safety software market grows at 9.5% CAGR through 2031. North America Leads: Dominates with 41.3% share via strong R&D. Cloud-Based Dominance: Holds 43.2% due to accessibility. AI Advancements: Enhance signal detection and analysis. COVID-19 Boost: Surged demand for real-time monitoring.

About DataM Intelligence 4Market Research:

DataM Intelligence 4Market Research is a market intelligence platform that gives access to syndicated, customized reports and consulting to its clients in one place. As a firm with rich experience in research and consulting across multiple domains, we are a one-stop solution that will cater to the needs of clients in key business areas. DataM Intelligence has an online platform whose coverage includes industries such as chemicals and materials, agriculture, health care services, animal feed, and food & beverages among others. Our platform has Insights on markets that uncover the latest market research data that are distinct from the competition. With coverage across 10 major industries in the marketplace research, DataM Intelligence benefits thousands of companies by helping them take their innovations early to the market, by providing a complete view of the market with statistical forecasts. Our strategy-centric framework and value-added services will let individuals and corporates with ease of access and custom personalization to research and markets.

Conclusion

The pharmacovigilance and drug safety software market promises robust expansion, driven by AI and regulatory needs, ensuring safer drug ecosystems globally.